Organisation paid for research Program year 2025 Source: CMS Open Payments

Valiance Clinical Research

Neither a doctor nor a teaching hospital

Research payments

$2,225,654

748 payments

Through program year 2025, Valiance Clinical Research is reported as receiving $2,225,654 in research payments, across 748 payments.

By program year

5 rows

Year	Kind	Amount	Payments
2025	Research	$2,045,797	143
2024	Research	$101,981	214
2023	Research	$17,182	217
2022	Research	$60,020	129
2021	Research	$674	45

Breakdown

Who paid Research payments · program years 2021–2025

Cleerly, Inc. $2,015,354 89 payments
Novartis Pharmaceuticals Corporation $95,776 3 payments
Ardelyx, Inc. $46,238 8 payments
Alnylam Pharmaceuticals Inc. $23,098 577 payments
GlaxoSmithKline, LLC. $20,353 5 payments
Boehringer Ingelheim Pharmaceuticals, Inc. $8,013 7 payments
Alexion Pharmaceuticals, Inc. $6,087 1 payment
Boehringer Ingelheim International GmbH $5,090 10 payments
Bayer HealthCare Pharmaceuticals Inc. $4,970 3 payments
Novo Nordisk AS $674 45 payments

Studies the money was for Research payments · program years 2021–2025

Transform $1,797,988 59 payments
Paramount $217,367 30 payments
A randomized, double-blind, placebo-controlled, multicenter, dose range finding study, to evaluate efficacy, safety and pharmacodynamics of QCZ484 in mild to moderate hypertensive patients $77,741 1 payment
Study to Evaluate the Use of Tenapanor As Core Therapy in the Treatment of Hyperphosphatemia (Optimize) $46,238 8 payments
A 52-Week, Randomised, Double-Blind, Double-Dummy, Parallel Group, Mul $20,353 5 payments
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of BION-1301 in Adults With IgA Nephropathy (The BEYOND Study) $18,035 2 payments
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) $14,969 461 payments
PoCP study in FSGS $12,755 12 payments
A Phase 2, Double Blind, Randomized, Placebo Controlled Study of Ravulizumab in Adult Participants with Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN) $6,087 1 payment
Finality Study #22618 $4,970 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.